Legare C, Berglund J, Duchesne E, Dumont N
Bioessays. 2024; 47(3):e202400216.
PMID: 39723693
PMC: 11848125.
DOI: 10.1002/bies.202400216.
Davey E, Legare C, Planco L, Shaughnessy S, Lennon C, Roussel M
JCI Insight. 2023; 8(14).
PMID: 37318869
PMC: 10443797.
DOI: 10.1172/jci.insight.163856.
Todorow V, Hintze S, Schoser B, Meinke P
Front Cell Dev Biol. 2023; 10:1007331.
PMID: 36699009
PMC: 9868253.
DOI: 10.3389/fcell.2022.1007331.
Espinosa-Espinosa J, Gonzalez-Barriga A, Lopez-Castel A, Artero R
Int J Mol Sci. 2022; 23(3).
PMID: 35163365
PMC: 8836095.
DOI: 10.3390/ijms23031441.
Todorow V, Hintze S, Kerr A, Hehr A, Schoser B, Meinke P
Int J Mol Sci. 2021; 22(16).
PMID: 34445314
PMC: 8395314.
DOI: 10.3390/ijms22168607.
A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1.
Zhang N, Bewick B, Xia G, Furling D, Ashizawa T
Front Genet. 2020; 11:594576.
PMID: 33362853
PMC: 7758406.
DOI: 10.3389/fgene.2020.594576.
Mechanisms and Regulation of RNA Condensation in RNP Granule Formation.
Tauber D, Tauber G, Parker R
Trends Biochem Sci. 2020; 45(9):764-778.
PMID: 32475683
PMC: 7211619.
DOI: 10.1016/j.tibs.2020.05.002.
Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.
Bargiela A, Sabater-Arcis M, Espinosa-Espinosa J, Zulaica M, de Munain A, Artero R
Proc Natl Acad Sci U S A. 2019; 116(50):25203-25213.
PMID: 31754023
PMC: 6911202.
DOI: 10.1073/pnas.1820297116.
miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.
Cerro-Herreros E, Sabater-Arcis M, Fernandez-Costa J, Moreno N, Perez-Alonso M, Llamusi B
Nat Commun. 2018; 9(1):2482.
PMID: 29946070
PMC: 6018771.
DOI: 10.1038/s41467-018-04892-4.
Cells of Matter- Models for Myotonic Dystrophy.
Matloka M, Klein A, Rau F, Furling D
Front Neurol. 2018; 9:361.
PMID: 29875732
PMC: 5974047.
DOI: 10.3389/fneur.2018.00361.
Bruno-3 regulates sarcomere component expression and contributes to muscle phenotypes of myotonic dystrophy type 1.
Picchio L, Legagneux V, Deschamps S, Renaud Y, Chauveau S, Paillard L
Dis Model Mech. 2018; 11(5).
PMID: 29716962
PMC: 5992612.
DOI: 10.1242/dmm.031849.
Diversification of the muscle proteome through alternative splicing.
Nakka K, Ghigna C, Gabellini D, Dilworth F
Skelet Muscle. 2018; 8(1):8.
PMID: 29510724
PMC: 5840707.
DOI: 10.1186/s13395-018-0152-3.
Alternative Splicing of Transcription Factors Genes in Muscle Physiology and Pathology.
Imbriano C, Molinari S
Genes (Basel). 2018; 9(2).
PMID: 29463057
PMC: 5852603.
DOI: 10.3390/genes9020107.
Splicing of human chloride channel 1.
Nakamura T, Ohsawa-Yoshida N, Zhao Y, Koebis M, Oana K, Mitsuhashi H
Biochem Biophys Rep. 2017; 5:63-69.
PMID: 28955807
PMC: 5600464.
DOI: 10.1016/j.bbrep.2015.11.006.
A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F, Bodycombe N, Haskell K, Sun Y, Wang E, Morris C
Hum Mol Genet. 2017; 26(16):3056-3068.
PMID: 28535287
PMC: 5886090.
DOI: 10.1093/hmg/ddx190.
As a Model Organism to Study RNA Toxicity of Repeat Expansion-Associated Neurodegenerative and Neuromuscular Diseases.
Koon A, Chan H
Front Cell Neurosci. 2017; 11:70.
PMID: 28377694
PMC: 5359753.
DOI: 10.3389/fncel.2017.00070.
Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I.
Bondy-Chorney E, Crawford Parks T, Ravel-Chapuis A, Jasmin B, Cote J
Rare Dis. 2016; 4(1):e1225644.
PMID: 27695661
PMC: 5027583.
DOI: 10.1080/21675511.2016.1225644.
Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases.
Jazurek M, Ciesiolka A, Starega-Roslan J, Bilinska K, Krzyzosiak W
Nucleic Acids Res. 2016; 44(19):9050-9070.
PMID: 27625393
PMC: 5100574.
DOI: 10.1093/nar/gkw803.
Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers.
Fernandez-Costa J, Llamusi B, Bargiela A, Zulaica M, Alvarez-Abril M, Perez-Alonso M
PLoS One. 2016; 11(2):e0150501.
PMID: 26919350
PMC: 4769077.
DOI: 10.1371/journal.pone.0150501.
In vivo assessment of muscle membrane properties in myotonic dystrophy.
Tan S, ZGraggen W, Boerio D, Turner C, Hanna M, Bostock H
Muscle Nerve. 2016; 54(2):249-57.
PMID: 26789642
PMC: 4940227.
DOI: 10.1002/mus.25025.